Related Experiment Video

Updated: Apr 27, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K

[Molecular targeted therapy in lymphoid leukemias]

Kensuke Kojima, Toshihiko Ando, Shinya Kimura

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |July 15, 2014
    PubMed

    Insights

    Novel molecular targeted therapies are enhancing lymphoid leukemia treatment by complementing chemotherapy. Continued research into agents like rituximab and ibrutinib is crucial for improving patient outcomes.

    Area of Science:

    • Hematology
    • Oncology
    • Pharmacology

    Context:

    • Traditional chemotherapy for lymphoid leukemias is evolving with new molecularly targeted drugs.
    • Molecular targeted therapies are being integrated with conventional treatments like rituximab and tyrosine kinase inhibitors.

    Purpose:

    • To review emerging molecular targeted therapies for lymphoid leukemias.
    • To discuss investigational agents for acute lymphoblastic leukemia, chronic lymphocytic leukemia, hairy cell leukemia, and adult T-cell leukemia.

    Summary:

    • This review covers novel molecular targeted agents including inotuzumab, blinatumomab, alemtuzumab, ofatumumab, ibrutinib, idelalisib, bafetinib, lenalidomide, ABT-199, and mogamulizumab.
    • These agents represent a significant advancement in the treatment landscape for various lymphoid leukemias.

    Impact:

    • Novel therapies offer potential for improved treatment efficacy and patient outcomes.
    • Continued research and clinical trials are essential to fully realize the benefits of these targeted approaches in lymphoid leukemia management.

    More Related Videos

    Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

    Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

    Published on: July 25, 2020

    6.5K
    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction09:44

    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

    Published on: January 29, 2019

    7.4K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.0K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    1.4K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    4.9K
    Tumor Immunotherapy01:27

    Tumor Immunotherapy

    Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
    2.5K
    Modified-Release Drug Delivery Systems: Site-Targeted01:24

    Modified-Release Drug Delivery Systems: Site-Targeted

    Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
    161
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    81